Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Adelman

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
Haematologica|February 24, 2001
Inhibition of CD40 ligand (CD154) in the treatment of factor VIII inhibitorsB M Ewenstein, W K Hoots, J M Lusher, et al.
Journal of the American College of Cardiology|February 6, 1999
Effect of transient abrupt vessel closure during otherwise successful angioplasty for unstable angina on clinical outcome at six months. Hirulog Angioplasty Study InvestigatorsR N Piana, W H Ahmed, B Chaitman, et al.
The American Journal of Cardiology|September 2, 1998
Effect of direct thrombin inhibition with Bivalirudin (Hirulog) on restenosis after coronary angioplastyJ E Burchenal, D S Marks, J Tift Mann, et al.
The New England Journal of Medicine|September 21, 1995
Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study InvestigatorsJ A Bittl, J Strony, J A Brinker, et al.
The American Journal of Cardiology|April 1, 1993
Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery diseaseC P Cannon, J M Maraganore, J Loscalzo, et al.
Journal of Abnormal Child Psychology|November 10, 2010
The Interaction Between Pubertal Timing and Peer Popularity for Boys and Girls: An Integration of Biological and Interpersonal Perspectives on Adolescent DepressionHanneke A Teunissen, Caroline B Adelman, Mitchell J Prinstein, et al.
Circulation|October 23, 1997
Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial InvestigatorsH D White, P E Aylward, M J Frey, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
Haematologica|February 24, 2001
Inhibition of CD40 ligand (CD154) in the treatment of factor VIII inhibitorsB M Ewenstein, W K Hoots, J M Lusher, et al.
Journal of the American College of Cardiology|February 6, 1999
Effect of transient abrupt vessel closure during otherwise successful angioplasty for unstable angina on clinical outcome at six months. Hirulog Angioplasty Study InvestigatorsR N Piana, W H Ahmed, B Chaitman, et al.
The American Journal of Cardiology|September 2, 1998
Effect of direct thrombin inhibition with Bivalirudin (Hirulog) on restenosis after coronary angioplastyJ E Burchenal, D S Marks, J Tift Mann, et al.
The New England Journal of Medicine|September 21, 1995
Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study InvestigatorsJ A Bittl, J Strony, J A Brinker, et al.
The American Journal of Cardiology|April 1, 1993
Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery diseaseC P Cannon, J M Maraganore, J Loscalzo, et al.
Journal of Abnormal Child Psychology|November 10, 2010
The Interaction Between Pubertal Timing and Peer Popularity for Boys and Girls: An Integration of Biological and Interpersonal Perspectives on Adolescent DepressionHanneke A Teunissen, Caroline B Adelman, Mitchell J Prinstein, et al.
Circulation|October 23, 1997
Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial InvestigatorsH D White, P E Aylward, M J Frey, et al.
Pageof 6